Revolutionizing Cancer Treatment Planning Tools, this Company’s Innovative Technologies are Changing the Game in the Fight Against Cancer…

Introducing: AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer.

The Company’s mission is to provide innovative treatment planning tools that optimize outcomes and quality of life for patients along the continuum of oncology care, from cancer screening through treatment and monitoring.

Download Research Report

Learn More about AccuStem Sciences, Inc. by gaining access to the latest research report

    Thanks for subscribing!
    Check your email for a confirmation message.

    With a $1.3BN market opportunity in breast cancer alone, AccuStem is an exciting first mover opportunity as it addresses needs no other company or product does!

    The Company’s mission is to provide innovative treatment planning tools that optimize outcomes and quality of life for patients along the continuum of oncology care, from cancer screening through treatment and monitoring.

    AccuStem is the only known company evaluating tumor “stemness” which can help determine the best course of treatment for patients and change clinical approach.

    “Stemness” indicates how much a tumor behaves like stem cells. Knowing a patient’s “stemness” levels can help determine the level of treatment aggressiveness each individual patient needs. This means, patients with a lower stemness level may avoid unnecessary treatments while patients with higher “stemness” levels can attack the cancer more aggressively with better outcome. 

    Breast cancer is one of the most common types of cancer today. According to the American Cancer Society, approximately 297,790 new cases of invasive breast cancer will be diagnosed in women in 2023 in the United States alone. 

    The Company has an estimated market opportunity of a massive $1.3BN in breast cancer alone!

    AccuStem Sciences, Inc. (OTCQB: ACUT) is a trailblazer in the oncology treatment planning tools market and its technology has the potential to be a total game-changer for cancer patients!

    ACUT recently extended its partnership with Instituto Europeo di Oncologia (IEO), one of the most renowned comprehensive cancer centers in Europe. This exciting milestone will help support the company’s mission. 

    The Company’s technology, StemPrintER has been shown to outperform the current market leader in risk of recurrence testing for women with early-stage breast cancer.

    This study conducted by investigators from the IEO in Milan and The Royal Marsden Hospital in London evaluated patients from the TransATAC trial, which is a well-known clinical trial that compared different treatments for early-stage breast cancer. The study included an evaluation of several breast cancer risk scoring assays, including the market-leading OncotypeDX test from Exact Sciences Corporation (NASDAQ: EXAS), which makes $600M annually!

    The study found that AccuStem's StemPrintER test was effective at predicting the likelihood of distant recurrence of breast cancer, with high-risk patients up to 4 times more likely to experience recurrence than low-risk patients. Additionally, StemPrintER was found to outperform the OncotypeDX test in stratifying patients based on their risk of breast cancer recurrence!

    AccuStem Sciences, Inc. (OTCQB: ACUT) outperforming the market leader makes the Company a first mover opportunity!


    1. Innovative Technology: AccuStem's StemPrintER was found to outperform the market-leading OncotypeDX which makes $600M annually.
    2. Massive Market Potential: According to a recent market research report, the global market for breast cancer diagnostics, including genomic tests like OncotypeDX, is projected to grow to over $8 billion by 2027. With an estimated market opportunity of a massive $1.3BN in breast cancer alone, the Company is well positioned to capture this market opportunity.
    3. Profit Margins: The Company’s profit margins are projected to be similar to large pharma companies reaching 90% at scale.
    4. Strong Acquisition Target: “Stemness” is applicable to all solid tumor types which makes ACUT a strong acquisition target as no one else is doing this!
    5. Strong Intellectual Property Portfolio: ACUT has a strong intellectual property portfolio, including multiple issued and pending patents, which can provide a competitive advantage and help protect its market position.
    6. Successful Clinical Trials: AccuStem's technology has undergone successful clinical trials with patients and the analyses included more than 3,000 patients. The trials have demonstrated promising results in predicting the likelihood of breast cancer recurrence and informing surgical approach.
    7. Addressing Unmet Needs: ACUT’s technology is designed to address unmet needs in cancer diagnosis defining optimal surgical intervention for patients with early breast cancer diagnosis. As such, the company's technology has the potential to fill a significant gap in the current standard of care, which can drive adoption and revenue growth.
    8. Experienced Management Team: The company's management team includes experienced leaders with a track record of success in the biotechnology industry, which can help guide the company's growth and navigate potential challenges.
    9. Strong Partnerships: AccuStem has established partnerships with several leading academic institutions and biotechnology companies, which can provide access to additional resources, expertise, and potential collaboration opportunities.
    10. Diversified Product Pipeline: In addition to its flagship StemPrintER technology, AccuStem has a diversified product pipeline plan that includes treatment planning tools for other types of cancer.

    With an estimated market opportunity of a massive $1.3BN in breast cancer alone, AccuStem Sciences, Inc. (OTCQB: ACUT) is an innovative game-player in the oncology market to have on your watch-list!

    The breast cancer market is a large and growing segment of the healthcare industry that has significant unmet needs. According to a recent market research report, the global market for breast cancer diagnostics, including genomic tests like OncotypeDX, is projected to grow to over $8 billion by 2027. 

    This growth can be attributed to several different factors, including increasing diagnoses of breast cancer worldwide, advancements in diagnostic technologies, and a growing focus on personalized medicine and targeted therapies.

    AccuStem Sciences, Inc. (OTCQB: ACUT)’s disruptive technology is an important player in the risk assessment of cancer patients as it answers important clinical questions and can point to surgical intervention to improve patient outcomes.

    About the Company:

    Founded in 2020 as a spinoff from Tiziana Life Sciences to commercialize a wide array of oncology products, AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for patients with cancer. The Company plans to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, the company believes its tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making and better possibilities of successful outcomes.

    Stemness in Cancer

    “Stemness” indicates how much a tumor behaves like stem cells. This characteristic is often associated with tumor aggressiveness, resistance to treatment, and higher rates of recurrence.  Levels of stemness are a key feature for understanding cancer progression and in many cases the source of its survival.

    Understanding the level of “stemness” in a patient's tumor can provide valuable insights into its biology, which in turn can help guide treatment decisions and improve patient outcomes.

    This is why the world needs technology like AccuStem's StemPrintER technology. By testing for stemness in breast cancer cells, StemPrintER has the potential to provide more accurate and personalized risk assessments for patients, as well as identify those who are at higher risk for recurrence and could benefit from more aggressive treatment strategies. 

    • High “stemness” in tumors is considered a primary rationale for disease recurrence and/or lack of response to chemotherapy and radiation 
    • Surgery may be the only way to effectively kill cancer stem cells or high “stemness” tumors

    ACUT’s Breast Cancer Program:

    • In-licensed StemPrintER assay from Instituto Europeo di Oncologia (IEO) US and EU patents approved 
    • Planning to address unanswered surgical clinical questions with its assay maximizing first mover advantage
    • The Company’s assay has been validated in multiple clinical trials enrolling 3,000 patients
    • Planning on submitting compelling new data to the 2023 San Antonio Breast Cancer Symposium (SABCS) for a new indication in breast cancer
    •  Will expand into offering high value ancillary testing
    • In a pivotal study, StemPrintER outperformed the market leading OncotypeDX test, which makes $600M annually!

    ACUT’s Stemness Program:

    • “Stemness” technology is applicable to multiple solid tumor types giving the Company numerous 1st mover opportunities pursuing signal seeking in lung and prostate cancers 
    • Clinical questions identified via work with leading lung and prostate physicians
    • StemPrintER evaluated in a Cancer Genome Atlas lung cancer cohort

    Opportunity for ACUT in Lung Cancer:

    2M+ new lung cancer diagnoses annually 

    • Currently no other genomic tests inform risk of recurrence and whether a patient should have surgery or radiation when considering a definitive treatment plan

    StemPrintER may inform surgical approach in patients with early stage lung cancer

    Opportunity for ACUT in Prostate Cancer:

    1.4M+ new prostate cancer diagnoses annually 

    • Currently no other genomic tests inform risk of recurrence and whether a patient should have surgery or radiation when considering a definitive treatment plan.

    StemPrintER may inform surgical approach  in patients with localized prostate cancer


    With a leadership team that has approximately 60 combined years of experience in the oncology diagnostics sector, this team has a proven track record of successful launch/relaunch strategies.

    Wendy Blosser
    Chief Executive Officer 

    Wendy brings 25 years of success launching, relaunching and building organizations in diagnostic, surgical and capital sales, with a focus in Oncology and Women’s Health. She has achieved record revenue growth at a variety of organizations from early-stage start ups to Fortune 500 companies. Most recently, Wendy has served as CCO at Agendia, Animated Dynamics and Biodesix. Prior to Biodesix, Wendy served as VP of Sales with Integrated Oncology (LabCorp subsidiary) where she led the 

    successful integration of Genzyme Genetics following its acquisition for $925M. Before joining Integrated Oncology, she held several leadership roles with Cytyc Corporation prior to its $6.2B acquisition by Hologic.

    Jeff Fensterer
    Chief Operating Officer

    Jeff has spent the last 20 years with start ups at various organizational stages, leading marketing and product strategy in his most recent roles at Agendia, Animated Dynamics and Biodesix. His scientific expertise and keen commercial perspective enable organizations to take clinical data and translate it into impactful product messaging and publication strategies. His exceptional track record in long-term strategic planning is enhanced by experience in a broad spectrum of roles including marketing, sales, R&D, market access, lab operations, clinical development, business development and IT. Jeff holds a MBA from Carnegie Mellon University.

    Joe Flanagan
    Chief Business Officer

    Joe has 25 years of sales excellence experience and is one of the most sought after talents in Oncology. He is a strategic expert, playing a leading role in the commercial development and successful launch of several product offerings from early-stage diagnostic start ups to large pharmaceutical companies. Prior to joining Accustem, Joe served as the VP of Sales for Precision Therapeutics as well as the VP of Market Development for Biodesix and Agendia. During his tenure, record revenues were realized as a result of his efforts to enhance the clinical agility and logistical focus of each company’s sales team. Most recently, he led strategic development efforts with Ambry Genetics’ Oncology franchise.

    Keeren Shah
    Chief Finance Officer

    Keeren has held a variety of leadership roles in Finance over the last 20 years. In addition to serving as AccuStem’s Chief Financial Officer, she also serves as the Chief Financial Officer of OKYO Pharma Ltd, Tiziana Life Sciences, Ltd. and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining this portfolio of companies, Keeren spent 10 years at Visa, Inc. as a senior leader on its Finance team where she was responsible for key financial controller activities, financial planning and analysis, core processes as well as leading and participating in key transformation programs including Visa Inc.’s initial public offering. Before joining Visa, Keeren also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of arts with honours in Economics and is a member of the Chartered Institute of Management Accountants.

    In Summary…

    ACUT’s mission is to provide treatment planning tools to address important, clinical needs that have previously not been answered across a spectrum of tumor types, making this Company an exciting first mover opportunity!

    AccuStem’s disruptive technology could be integral for patients with cancer, as it could improve outcomes and reduce healthcare costs while determining the optimal surgical approach for patients. 

    With an estimated market opportunity of a massive $1.3BN in breast cancer alone and a 90% margin opportunity, ACUT is a trailblazer with massive market opportunity to keep your eye on.

    The Company’s technology, StemPrintER has been shown to outperform the current market leader in risk of recurrence testing for women with early-stage breast cancer making this an exciting Company to keep your eye on in a massive market!

    With strong patent protection, pharma-like margins, successful clinical trials that outperform the market leader, and building a body of evidence that makes ACUT a strong acquisition target, AccuStem Sciences, Inc. (OTCQB: ACUT), is a massive revenue opportunity and should be on your watch-list!


    Learn More about AccuStem Sciences, Inc.  by gaining access to the latest 
    research report

    Download Report




    SCD Media LLC (d/b/a “Smallcaps Daily”), hereinafter referred to as “Smallcaps Daily,” and their affiliates and control persons (the “Publisher”) are in the business of publishing favorable information and/or advertisements (the “Information”) about the securities of publicly traded companies (each an “Issuer” or collectively the “Issuers”) in exchange for compensation (the “Campaigns”). Persons receiving the Information are referred to as the “Recipients.” The person or entity paying the Publisher for the Campaign is referred to herein as the “Paying Party”. The Paying Party may be an Issuer, an affiliated or non-affiliate shareholder of an Issuer, or another person hired by the Issuer or an affiliate or non-affiliate shareholder of the Issuer. The nature and amount of compensation paid to the Publisher for the Campaign and creating and/or publishing the Information about each Issuer is set forth below under the heading captioned, “Compensation”.

    This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment.

    Nothing on this website should be considered personalized financial advice. Any investments recommended herein should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.


    Smallcaps Daily, its managers, its employees, affiliates, and assigns (collectively the "Publisher") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.


    Release of Liability: through use of this website, viewing or using you agree to hold Smallcaps Daily, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Smallcaps Daily encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the company profiled or is available from public sources and Smallcaps Daily makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled company. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Smallcaps Daily strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Smallcaps Daily’s full disclosure is to be read and fully understood before using Smallcaps Daily's website, or joining Smallcaps Daily's email or text list. From time to time, Smallcaps Daily will disseminate information about a company via website, email, sms, and other points of media. By viewing Smallcaps Daily's website and/or reading Smallcaps Daily's email or text newsletter you are agreeing to this ----> https://Smallcaps All potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation.  

    If you have questions or concerns about a product you’ve seen in one of our emails, emails, text newsletters or SMS, we encourage you to reach out to that company directly.

    Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by the owner of Smallcaps Daily. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to Smallcaps Daily. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editors, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here.


    In compliance with section 17(b) of the Securities Act we are disclosing that we have been compensated a fee pursuant to an agreement between Smallcaps Daily and IA Media LLC (d/b/a/ “IA Media”) hereinafter referred to as IA Media. Please see IA Media’s disclosure page here.  Small Caps Daily was hired by IA Media for a period beginning May 2023 and ending July 2023 to publicly disseminate information about Accustem Sciences Inc. via website, email, and SMS. We were paid fifty thousand usd via ACH. Readers are advised to review SEC periodic reports: forms 10Q 10K, form 8K, insider reports, forms 3, 4, 5 schedule 13d. Smallcaps Daily is compliant with the CAN-SPAM Act of 2003. Smallcaps Daily does not offer investment advice or analysis, and Smallcaps Daily further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. The private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact but may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results in preparing this publication. Smallcaps Daily has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. Investors should not rely on the information contained on this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, Smallcaps Daily and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Smallcaps Daily is not responsible for any claims made by the companies advertised herein, nor is Smallcaps Daily responsible for any other promotional firm, its program, or its structure. Smallcaps Daily is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission, or FINRA. 


    Copyright © 2023 Smallcaps Daily. All rights reserved.